Search
Perflutren
go.drugbank.com/drugs/DB00556ApprovedInvestigationalThe difference in density between the gas-filled bubbles and the blood around them creates an increased level of contrast visible in the resulting ultrasound image. … When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultrasound machine.
Categories: Amino Acids, Peptides, and ProteinsOteracil
go.drugbank.com/drugs/DB03209ApprovedInvestigationalBy mimicking a class of compounds called "pyrimidines" that are essential components of RNA and DNA, 5-FU is able to insert itself into strands of DNA and RNA, thereby halting the replication process necessary … Approved by the European Medicines Agency (EMA) in March 2011, Oteracil is available in combination with [DB09257] and [DB09256] within the commercially available product "Teysuno".
Padeliporfin
go.drugbank.com/drugs/DB15575ApprovedInvestigationalPadeliporfin is a water-soluble chlorophyll derivative and cytotoxic photosensitizer used for vascular-targeted photodynamic therapy for malignancies. … [A244699] Padeliporfin was first approved by the European Commission on November 10, 2017, for the treatment of low-risk prostate cancer in adults meeting certain clinical criteria.[L39799]
Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating AgentsAllogeneic Cardiosphere-Derived Cells
go.drugbank.com/drugs/DB15744InvestigationalCardiosphere-derived cells (CDCs) are derived from human neonatal heart tissue with a distinct antigenic profile (CD105+, CD45-, and CD90low). … TNFa, IFN-y, IL-1B, and IL-15). The anti-inflammatory effects of CDC work through polarizing macrophages and restoring tissue function.
Vedolizumab
go.drugbank.com/drugs/DB09033ApprovedInvestigational[L48216] Vedolizumab was developed by Takeda and approved by the FDA under the brand name ENTYVIO for the maintenance therapy of moderately to severely active Ulcerative Colitis and Crohn’s Disease … [A261576] Vedolizumab is administered by IV infusion over a period of 30 minutes; after the first dose, it is given again at two and six weeks and then every 8 weeks thereafter.
Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating AgentsVatalanib
go.drugbank.com/drugs/DB04879InvestigationalVatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors.
Gantenerumab
go.drugbank.com/drugs/DB12034Investigational[A244705, A244710, A244745] Gantenerumab is a fully human IgG1κ monoclonal antibody derived from the MorphoSys HuCAL®-Fab1 phage display library and subsequently optimized by _in vitro_ CDR cassette … As the classical view of AD pathology posits that Aβ accumulation triggers tau hyperphosphorylation and aggregation to form NFTs and cause neurodegeneration, large efforts have gone into developing treatments
Categories: Amino Acids, Peptides, and ProteinsMazindol
go.drugbank.com/drugs/DB00579ApprovedMazindol is a tricyclic anorexigenic agent that is unrelated to and less toxic than [amphetamine], but with some similar side effects. … It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter.
Categories: Alimentary Tract and Metabolism, Anorexigenic Agents & Respiratory and CNS StimulantsAZD3409
go.drugbank.com/drugs/DB04893ExperimentalPhase I trials were initiated January 2003, and were ongoing as of February 2004. As of February 2007 the development of AZD3409 had been discontinued.
Dipotassium phosphate
go.drugbank.com/drugs/DB09414ApprovedInvestigationalDipotassium phosphate (K2HPO4) is a highly water-soluble salt often used as a fertilizer and food additive as a source of phosphorus and potassium as well as a buffering agent.
Mixtures: Ionosol B and Dextrose